#1 Clinical Trials Search in Europe

(2R,3S)-2-Amino-3-Hydroxy-3-Pyridin-4-Yl-1-Pyrrolidin-1-Ylpropan-1-One (2R,3R)-2,3-Dihydroxybutanedioic Acid

This article discusses the ongoing clinical trials of RL-007, a promising new drug being studied for the treatment of cognitive impairment associated with schizophrenia (CIAS). RL-007 is currently undergoing Phase II trials to assess its safety, efficacy, and potential benefits for patients with schizophrenia who experience cognitive difficulties. The study aims to provide valuable insights into how this medication may improve cognitive function and overall quality of life for individuals living with schizophrenia.

Table of Contents

Overview of RL-007

RL-007 is a new medication being studied for its potential to improve cognitive impairment associated with schizophrenia (CIAS)[1]. The scientific name for this drug is (2R,3S)-2-amino-3-hydroxy-3-pyridin-4-yl-1-pyrrolidin-1-ylpropan-1-one (2R,3R)-2,3-dihydroxybutanedioic acid. It’s also known as a “procognitive neuromodulator,” which means it’s designed to help improve thinking and mental processes[1].

How RL-007 Works

While the exact mechanism of RL-007 is not fully described in the available information, it’s classified as a procognitive neuromodulator. This suggests that it works by altering brain activity in ways that may improve cognitive functions like memory, attention, and problem-solving skills[1]. These are areas where people with schizophrenia often experience difficulties.

Clinical Study Details

A clinical trial is currently underway to evaluate RL-007. This study is described as an “adaptive, randomized, placebo-controlled, double-blind study”[1]. Let’s break down what this means:

  • Adaptive: The study can be adjusted based on early results.
  • Randomized: Participants are randomly assigned to different groups.
  • Placebo-controlled: Some participants will receive a placebo (a substance with no active drug) for comparison.
  • Double-blind: Neither the participants nor the researchers know who is receiving the actual drug or the placebo.

The main goal of this study is to assess how RL-007 affects cognitive performance in people diagnosed with schizophrenia. The researchers will also be looking at the safety and tolerability of the drug[1].

Who Can Participate in the Study?

The study is looking for participants who meet specific criteria, including[1]:

  • Adults between 18 and 55 years old
  • Diagnosed with schizophrenia for at least 6 months
  • Currently taking a stable dose of a single atypical antipsychotic medication (except clozapine)
  • Have relatively stable symptoms (not severe)
  • Do not have other major psychiatric disorders or significant health issues

There are many other specific inclusion and exclusion criteria that the study doctors will use to determine if someone is eligible to participate.

Study Design and Duration

The study is divided into three main periods[1]:

  1. Screening Period: This lasts up to 30 days and is used to determine if a person is eligible for the study.
  2. Treatment Period: This lasts 6 weeks. Participants will be randomly assigned to one of three groups: two groups will receive different doses of RL-007, and one group will receive a placebo. All participants will continue their regular antipsychotic medication.
  3. Follow-up Period: This lasts 2 weeks after the treatment ends, to check on the participants’ health.

The total duration of participation is about 12 weeks, with at least 3 in-person visits to the study site and 4 phone calls[1].

What Will Be Measured in the Study?

The study will use several tests to measure cognitive function and other aspects of the participants’ health[1]:

  • MATRICS Consensus Cognitive Battery (MCCB): This is a set of tests that measure different aspects of cognition, including attention, memory, and problem-solving.
  • Clinical Global Impression – Severity (CGI-S): This measures the overall severity of the participant’s condition.
  • Virtual Reality Functional Capacity Assessment Tool (VRFCAT): This uses virtual reality to assess how well participants can perform everyday tasks.

The researchers will also monitor participants’ physical health through various tests and examinations.

Safety Considerations

As with any clinical trial, participant safety is a top priority. The study includes several measures to ensure safety[1]:

  • Regular check-ups and phone calls to monitor participants’ health
  • Tests to check vital signs, heart function (ECG), and blood and urine samples
  • Monitoring for any side effects or adverse events
  • Use of a tool called the Columbia-Suicide Severity Rating Scale (C-SSRS) to assess any risk of suicide

It’s important to note that RL-007 is still an experimental drug, and its full effects and potential side effects are not yet known. This study aims to gather more information about its safety and effectiveness.

Aspect Details
Drug Name RL-007 ((2R,3S)-2-Amino-3-Hydroxy-3-Pyridin-4-Yl-1-Pyrrolidin-1-Ylpropan-1-One (2R,3R)-2,3-Dihydroxybutanedioic Acid)
Study Phase Phase II
Target Condition Cognitive Impairment Associated with Schizophrenia (CIAS)
Study Design Adaptive, randomized, placebo-controlled, double-blind, parallel, 3-arm, multi-center study
Primary Endpoint Change in MCCB neurocognitive composite score from baseline to Week 6
Key Secondary Endpoints Changes in specific MCCB domains, CGI-S, VRFCAT, safety assessments
Treatment Duration 6 weeks
Total Study Duration Approximately 12 weeks per participant
Key Inclusion Criteria Adults 18-55 years, diagnosed with schizophrenia for ≥6 months, stable on single atypical antipsychotic
Key Exclusion Criteria Substance abuse, significant medical conditions, suicide risk, prior RL-007 exposure

FAQ

  • What is RL-007 and what is it being studied for? RL-007 is an investigational drug being studied for the treatment of cognitive impairment associated with schizophrenia (CIAS). It is currently in Phase II clinical trials to evaluate its safety and effectiveness in improving cognitive function in patients with schizophrenia.
  • Who is eligible to participate in the RL-007 clinical trial? Eligible participants are adults aged 18-55 with a diagnosis of schizophrenia for at least 6 months, who are currently stable on a single atypical antipsychotic medication. They must meet specific criteria regarding symptom severity and overall health status.
  • How long does the clinical trial last? The clinical trial lasts approximately 12 weeks for each participant. This includes a 6-week treatment period and a 2-week follow-up period, with several on-site visits and phone calls throughout the study.
  • What are the main objectives of the RL-007 clinical trial? The main objectives are to assess the effects of RL-007 on cognitive performance in participants with schizophrenia, evaluate its safety and tolerability, and measure other efficacy outcomes of interest.
  • How is cognitive function measured in this study? Cognitive function is primarily measured using the MATRICS Consensus Cognitive Battery (MCCB), which assesses various aspects of cognition such as processing speed, attention, working memory, and problem-solving. The study also uses other tools like the Virtual Reality Functional Capacity Assessment Tool (VRFCAT) to evaluate functional capacity.

Ongoing Clinical Trials on (2R,3S)-2-Amino-3-Hydroxy-3-Pyridin-4-Yl-1-Pyrrolidin-1-Ylpropan-1-One (2R,3R)-2,3-Dihydroxybutanedioic Acid

  • Study on RL-007 for Improving Cognitive Impairment in Schizophrenia Patients

    Not recruiting

    2 1
    Investigated diseases:
    Investigated drugs:
    Bulgaria Czechia Poland

Glossary

  • Schizophrenia: A serious mental disorder characterized by distortions in thinking, perception, emotions, language, sense of self, and behavior.
  • Cognitive Impairment: Difficulties with mental processes such as thinking, remembering, and problem-solving, which can affect daily functioning.
  • CIAS: Cognitive Impairment Associated with Schizophrenia, referring to the cognitive difficulties often experienced by individuals with schizophrenia.
  • MCCB: MATRICS Consensus Cognitive Battery, a standardized test used to assess cognitive function in people with schizophrenia.
  • Placebo: A substance with no active therapeutic effect, used as a control in testing new drugs.
  • Double-blind: A study design where neither the participants nor the researchers know who is receiving the actual treatment or placebo.
  • Efficacy: The ability of a treatment to produce a desired or intended result.
  • Atypical Antipsychotic: A newer class of antipsychotic medications used to treat schizophrenia, often with fewer side effects than older antipsychotics.
  • PANSS: Positive and Negative Syndrome Scale, a medical scale used for measuring symptom severity of patients with schizophrenia.
  • VRFCAT: Virtual Reality Functional Capacity Assessment Tool, a test used to evaluate a person's ability to perform everyday tasks in a simulated environment.

References

  1. http://clinicaltrials.eu/trial/study-on-rl-007-for-improving-cognitive-impairment-in-schizophrenia-patients/